Skip to search formSkip to main contentSkip to account menu

Topotecan Hydrochloride

Known as: Hydrochloride, Topotecan, Oral Topotecan Hydrochloride, (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7] indolizino[1,2-b] quinoline-3,14-(4H,12H)-dione Monohydrochloride 
The hydrochloride salt of a semisynthetic derivative of camptothecin with antineoplastic activity. During the S phase of the cell cycle, topotecan… 
National Institutes of Health

Related topics

Related topics

25 relations

Broader (2)

CamptothecinTopotecan
Carcinoma, Small CellDNA Replication InhibitionDNA Strand BreakLactation

Narrower (3)

HycamtamineHycamtinSK&F-104864-A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
A randomized multicenter phase III trial of topotecan monotherapy versus topotecan + etoposide versus topotecan + gemcitabine for second-line treatment of recurrent ovarian cancer.
5030 Background: Topotecan combined with etoposide (GINECO 1998) and gemcitabine (NOGGO 2001) proved effective for second-line… 
2005
2005
Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia
Purpose: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and… 
Review
2004
Review
2004
Emerging role of weekly topotecan in recurrent small cell lung cancer.
Small cell lung cancer (SCLC) is an aggressive tumor that often metastasizes before the primary cancer is diagnosed. Patients… 
Review
2002
Review
2002
Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?
Relapsed ovarian cancer and small cell lung cancer are frequently treated with topotecan (Hycamtin), for which the standard dose… 
2002
2002
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
PURPOSE To determine whether agents that target topoisomerase I and II could be administered sequentially. DESIGN A Phase I… 
2000
2000
A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
BACKGROUND As suggested by preclinical trials, prolonged administration of topotecan, a reversible inhibitor of topoisomerase-I… 
2000
2000
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines
Purpose: We have previously shown that neuroblastoma cell lines established from patients after intensive chemotherapy show… 
2000
2000
Population pharmacokinetics of topotecan: intraindividual variability in total drug
Abstract The inter- and intraindividual variabilities in topotecan clearance (CL) were explored using a population… 
Highly Cited
1998
Highly Cited
1998
Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Topotecan undergoes both renal and hepatic elimination, with topotecan urinary recovery ranging from 60 to 70%. We evaluated the… 
1998
1998
O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.
During topotecan analysis of clinical urine samples, an additional peak eluting just after the solvent front was observed. This… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)